Cancer Immunology Reserch

Cancer Immunol Res. 2025 Sep 18. doi: 10.1158/2326-6066.CIR-24-1011. Online ahead of print. ABSTRACT The immunosuppressive tumor microenvironment (TME) remains a major barrier to effective immunotherapy in gastric cancer (GC). Here, we identified the E3 ubiquitin ligase BFAR as a critical regulator of neutrophil-mediated immune evasion through the S100A8/A9-BFAR-PRP19-YBX1 signaling axis. Multi-omics analyses revealed that BFAR … Read more

Cancer Immunol Res. 2025 Sep 10. doi: 10.1158/2326-6066.CIR-25-0075. Online ahead of print. ABSTRACT Despite recent progress within the field of immuno-oncology, immune suppression in the tumor microenvironment, defective antigen presentation, and low levels of tumor-specific T cells are key limitations of current cancer immunotherapies. CD40-targeting immunotherapies hold promises for addressing these limitations across solid tumors. … Read more

Cancer Immunol Res. 2025 Sep 9. doi: 10.1158/2326-6066.CIR-25-0174. Online ahead of print. ABSTRACT Natural killer (NK) cell licensing is an educational process that enhances responsiveness to activating signals in maturing NK cells and is predominantly regulated by major histocompatibility complex (MHC) class I-specific inhibitory signals. However, the role of non-MHC signalling in this process remains … Read more

Cancer Immunol Res. 2025 Sep 9. doi: 10.1158/2326-6066.CIR-24-0440. Online ahead of print. ABSTRACT Ovarian cancer remains a major health threat with limited treatment options available. It is characterized by immunosuppressive tumor microenvironment (TME) maintained by tumor-associated macrophages (TAMs) hindering anti-tumor responses and immunotherapy efficacy. Here we show that targeting retinoblastoma protein (Rb) by disruption of … Read more

Cancer Immunol Res. 2025 Sep 8:OF1. doi: 10.1158/2326-6066.CIR-25-0804. Online ahead of print. NO ABSTRACT PMID:40920201 | DOI:10.1158/2326-6066.CIR-25-0804

Cancer Immunol Res. 2025 Sep 8. doi: 10.1158/2326-6066.CIR-25-0527. Online ahead of print. ABSTRACT Antibody-based therapies have revolutionized cancer treatment but have several limitations. These include: down-regulation of the target antigen; mutation of the target epitope; or in the case of antibody drug conjugates (ADCs), resistance to the chemotherapy warhead. Since TROP2-targeted therapy with ADCs yields … Read more

Cancer Immunol Res. 2025 Sep 8. doi: 10.1158/2326-6066.CIR-25-0575. Online ahead of print. ABSTRACT Pancreatic ductal adenocarcinoma (PDA) is defined by a myeloid-enriched microenvironment and has shown remarkable resistance to immune checkpoint blockade (e.g., PD-1 and CTLA-4). Here, we sought to define the role of myeloid immunosuppression in immune resistance in PDA. We report that depletion … Read more

Cancer Immunol Res. 2025 Sep 4. doi: 10.1158/2326-6066.CIR-25-0488. Online ahead of print. ABSTRACT Tumor-associated macrophages (TAMs) display remarkable functional heterogeneity, yet the molecular mechanisms driving their diverse phenotypes remain elusive. Using CRISPR screens in primary macrophages, we identified tumor-derived factors, including lactic acid, PGE2, and GM-CSF, as key modulators of TAM polarization. These factors interact … Read more

Cancer Immunol Res. 2025 Sep 4. doi: 10.1158/2326-6066.CIR-24-1074. Online ahead of print. ABSTRACT Liver metastases are associated with poor cancer outcomes in many solid malignancies, but the factors influencing the trajectory of patients with liver metastases are poorly defined. It is known that liver metastases suppress systemic antitumor immunity; however, the underlying mechanisms remain incompletely … Read more

Cancer Immunol Res. 2025 Sep 4. doi: 10.1158/2326-6066.CIR-25-0086. Online ahead of print. ABSTRACT The discovery of immune checkpoints and the rapid growth of immuno-oncology (IO) have sparked efforts to utilize the immune system to treat a wide range of cancer types/subtypes. While the major focus of IO over the past decades has been to manipulate … Read more